ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 2, 2015, Pages 234-248

  Zhang, Jiong ^a,c   Yanez, David ^b   Floege, Anna ^a   Lichtnekert, Julia ^a   Krofft, Ronald D ^a   Liu, Zhi Hong ^c   Pippin, Jeffrey W ^a   Shankland, Stuart J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

enalapril; Focal segmental glomerulosclerosis; glomerulosclerosis; parietal epithelial cell; podocyte; regeneration; repair

Indexed keywords

ALBUMIN; CELL PROTEIN; CREATININE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYTOTOXIC ANTIPODOCYTE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE; DRINKING WATER; ENALAPRIL; ENDOTHELIAL CELL ANTIBODY; HYDRALAZINE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHO MITOGEN ACTIVATED PROTEIN KINASE; PODOCYTE PROTEIN; PROTEIN KINASE; SYNAPTOPODIN; TRANSCRIPTION FACTOR PAX2; UNCLASSIFIED DRUG; WT 1 PROTEIN; ACTIN BINDING PROTEIN; ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PAX2 PROTEIN, MOUSE; PROTEIN BINDING; REPRESSOR PROTEIN; SYNPO PROTEIN, MOUSE; WT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIVARIATE ANALYSIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG ACTIVITY; DRUG PROTEIN BINDING; ENZYME INHIBITION; EPITHELIUM CELL; EXPERIMENTAL MOUSE; FOCAL GLOMERULOSCLEROSIS; GLOMERULAR EPITHELIAL CELL; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; KIDNEY FUNCTION; MOUSE; NONHUMAN; PHASE TRANSITION; PODOCYTE; RENAL SYSTEM PARAMETERS; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; URINARY ALBUMIN TO CREATININE RATIO; ANIMAL; BIOASSAY; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SYSTOLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES; BLOOD PRESSURE; CELL COUNT; CELL PROLIFERATION; ENALAPRIL; ENDPOINT DETERMINATION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; MICE; MICROFILAMENT PROTEINS; PAX2 TRANSCRIPTION FACTOR; PHOSPHORYLATION; PODOCYTES; PROTEIN BINDING; REPRESSOR PROTEINS; SYSTOLE;

EID: 84930904241     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314543910     Document Type: Article

References (57)

1. Loriga G, Vidili G, Ruggenenti P, et al. Renal hemodynamics and renoprotection. Nephron Clin Pract. 2008 ; 110: c213 - c219
2. Nishiyama A, Tamaki T, Masumura H, et al. Effects of semotiadil fumarate (SD-3211) on renal hemodynamics and function in dogs. Eur J Pharmacol. 1992 ; 218: 311-317
3. Ito S. Cardiorenal connection in chronic kidney disease. Clin Exp Nephrol. 2012 ; 16: 8-16
4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 ; 345: 861-869
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 ; 345: 851-860
6. Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: Effects of angiotensin converting enzyme inhibition. Diabetologia. 2002 ; 45: 1572-1576
7. Kelly DJ, Aaltonen P, Cox AJ, et al. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: Differing effects of anti-proteinuric therapies. Nephrol Dial Transplant. 2002 ; 17: 1327-1332
8. Nijenhuis T, Sloan AJ, Hoenderop JG, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011 ; 179: 1719-1732
9. Wennmann DO, Hsu HH, Pavenstadt H. The renin-angiotensin-aldosterone system in podocytes. Semin Nephrol. 2012 ; 32: 377-384
10. Camici M, Carpi A, Cini G, et al. Podocyte dysfunction in aging-related glomerulosclerosis. Front Biosci (Schol Ed). 2011 ; 3: 995-1006
11. Macconi D, Sangalli F, Bonomelli M, et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol. 2009 ; 174: 797-807
12. Benigni A, Morigi M, Rizzo P, et al. Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Am J Pathol. 2011 ; 179: 628-638
13. Rizzo P, Perico N, Gagliardini E, et al. Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. Am J Pathol. 2013 ; 183: 1769-1778
14. Wiggins RC. The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int. 2007 ; 71: 1205-1214
15. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005 ; 16: 2941-2952
16. Matsusaka T, Xin J, Niwa S, et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol. 2005 ; 16: 1013-1023
17. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech. 2002 ; 57: 189-195
18. Zhang J, Pippin JW, Krofft RD, et al. Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol. 2013 ; 304: F1375 - F1389
19. Griffin SV, Krofft RD, Pippin JW, et al. Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney Int. 2005 ; 67: 977-986
20. Logar CM, Brinkkoetter PT, Krofft RD, et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int. 2007 ; 72: 489-498
21. Vaughan MR, Pippin JW, Griffin SV, et al. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int. 2005 ; 68: 133-144
22. Ohse T, Vaughan MR, Kopp JB, et al. De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am J Physiol Renal Physiol. 2010 ; 298: F702 - F711
23. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol. 2009 ; 296: F213 - F229
24. Taniguchi Y, Pippin JW, Hagmann H, et al. Both cyclin I and p35 are required for maximal survival benefit of cyclin-dependent kinase 5 in kidney podocytes. Am J Physiol Renal Physiol. 2012 ; 302: F1161 - F1171
25. Zhang J, Pippin JW, Vaughan MR, et al. Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial cells in experimental glomerular disease. Nephron Exp Nephrol. 2012 ; 121: e23 - e37
26. Pichaiwong W, Hudkins KL, Wietecha T, et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol. 2013 ; 24: 1088-1102
27. Guo S, Kowalewska J, Wietecha TA, et al. Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol. 2008 ; 19: 1168-1176
28. Marshall CB, Krofft RD, Blonski MJ, et al. Role of smooth muscle protein SM22alpha in glomerular epithelial cell injury. Am J Physiol Renal Physiol. 2011 ; 300: F1026 - F1042
29. Pippin JW, Sparks MA, Glenn ST, et al. Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease. Am J Pathol. 2013 ; 183: 542-557
30. Zhang J, Hansen KM, Pippin JW, et al. De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am J Physiol Renal Physiol. 2012 ; 302: F571 - F580
31. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005 ; 23: 7212-7220
32. Ophascharoensuk V, Pippin JW, Gordon KL, et al. Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney Int. 1998 ; 54: 416-425
33. Brinkkoetter PT, Wu JS, Ohse T, et al. p35, the non-cyclin activator of Cdk5, protects podocytes against apoptosis in vitro and in vivo. Kidney Int. 2010 ; 77: 690-699
34. Hunter MG, Hurwitz S, Bellamy CO, et al. Quantitative morphometry of lupus nephritis: The significance of collagen, tubular space, and inflammatory infiltrate. Kidney Int. 2005 ; 67: 94-102
35. Jarad G, Pippin JW, Shankland SJ, et al. Dystroglycan does not contribute significantly to kidney development or function, in health or after injury. Am J Physiol Renal Physiol. 2011 ; 300: F811 - F820
36. Smeets B, Kuppe C, Sicking EM, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011 ; 22: 1262-1274
37. Roskoski R. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 2012 ; 66: 105-143
38. Cheng P, Alberts I, Li X. The role of ERK1/2 in the regulation of proliferation and differentiation of astrocytes in developing brain. Int J Dev Neurosci. 2013 ; 31: 783-789
39. Cheng J, Zhang W, Zhang XH, et al. ACEI/ARB therapy for IgA nephropathy: A meta analysis of randomised controlled trials. Int J Clin Pract. 2009 ; 63: 880-888
40. Tanaka R, Kon V, Yoshioka T, et al. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int. 1994 ; 45: 537-543
41. Griffin SV, Hiromura K, Pippin J, et al. Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology. Am J Pathol. 2004 ; 165: 1175-1185
42. Ihara G, Kiyomoto H, Kobori H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: Effect of angiotensin II blockade. J Hypertens. 2010 ; 28: 2289-2298
43. Kavvadas P, Weis L, Abed AB, et al. Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents. Hypertension. 2013 ; 61: 901-907
44. Gagliardini E, Corna D, Zoja C, et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol. 2009 ; 297: F1448 - F1456
45. Bariety J, Mandet C, Hill GS, et al. Parietal podocytes in normal human glomeruli. J Am Soc Nephrol. 2006 ; 17: 2770-2780
46. Romagnani P. Family portrait: Renal progenitor of Bowman's capsule and its tubular brothers. Am J Pathol. 2011 ; 178: 490-493
47. Sakamoto K, Ueno T, Kobayashi N, et al. The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis. Am J Physiol Renal Physiol. 2014 ; 306: F98 - F104
48. Schulte K, Berger K, Boor P, et al. Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. J Am Soc Nephrol. 2014 ; 25: 129-141
49. Wanner N, Hartleben B, Herbach N, et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol. 2014 ; 25: 707-716
50. Angelotti ML, Lazzeri E, Lasagni L, et al. Only anti-CD133 antibodies recognizing the CD133/1 or the CD133/2 epitopes can identify human renal progenitors. Kidney Int. 2010 ; 78: 620-621
51. Lasagni L, Ballerini L, Angelotti ML, et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells. 2010 ; 28: 1674-1685
52. Smeets B, Angelotti ML, Rizzo P, et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol. 2009 ; 20: 2593-2603
53. Greenblatt MB, Shim JH, Glimcher LH. Mitogen-activated protein kinase pathways in osteoblasts. Annu Rev Cell Dev Biol. 2013 ; 29: 63-79
54. Chambard JC, Lefloch R, Pouyssegur J, et al. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007 ; 1773: 1299-1310
55. Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 2013 ; 27: 900-915
56. Chang AM, Ohse T, Krofft RD, et al. Albumin-induced apoptosis of glomerular parietal epithelial cells is modulated by extracellular signal-regulated kinase 1/2. Nephrol Dial Transplant. 2012 ; 27: 1330-1343
57. Peired A, Angelotti ML, Ronconi E, et al. Proteinuria impairs podocyte regeneration by sequestering retinoic acid. J Am Soc Nephrol. 2013 ; 24: 1756-1768